Maryland State Retirement & Pension System Has $1.90 Million Stock Holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Maryland State Retirement & Pension System trimmed its holdings in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 4.6% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 24,278 shares of the company’s stock after selling 1,169 shares during the period. Maryland State Retirement & Pension System’s holdings in GE HealthCare Technologies were worth $1,898,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Darwin Wealth Management LLC acquired a new position in shares of GE HealthCare Technologies during the 3rd quarter worth about $31,000. Continuum Advisory LLC raised its holdings in shares of GE HealthCare Technologies by 101.8% in the 3rd quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock valued at $31,000 after purchasing an additional 168 shares during the period. Bank of Jackson Hole Trust bought a new stake in shares of GE HealthCare Technologies in the 4th quarter valued at about $32,000. OFI Invest Asset Management bought a new stake in shares of GE HealthCare Technologies in the 4th quarter valued at about $34,000. Finally, Flagship Wealth Advisors LLC bought a new stake in shares of GE HealthCare Technologies in the 4th quarter valued at about $34,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Citigroup upped their target price on shares of GE HealthCare Technologies from $103.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, February 13th. The Goldman Sachs Group raised shares of GE HealthCare Technologies from a “neutral” rating to a “buy” rating and upped their target price for the company from $85.00 to $100.00 in a report on Tuesday, March 11th. Jefferies Financial Group raised shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and upped their target price for the company from $95.00 to $103.00 in a report on Wednesday, January 8th. Finally, Wells Fargo & Company upped their target price on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the company an “overweight” rating in a report on Friday, February 14th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $98.75.

GE HealthCare Technologies Stock Down 0.4 %

Shares of GEHC opened at $81.49 on Friday. GE HealthCare Technologies Inc. has a 12 month low of $74.51 and a 12 month high of $94.80. The firm’s 50 day moving average is $87.02 and its 200-day moving average is $86.02. The stock has a market capitalization of $37.27 billion, a PE ratio of 18.82, a P/E/G ratio of 3.19 and a beta of 1.13. The company has a current ratio of 1.04, a quick ratio of 0.83 and a debt-to-equity ratio of 0.88.

GE HealthCare Technologies (NASDAQ:GEHC) last announced its earnings results on Thursday, February 13th. The company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.26 by $0.19. GE HealthCare Technologies had a net margin of 10.13% and a return on equity of 25.74%. The company had revenue of $5.32 billion for the quarter, compared to analysts’ expectations of $5.33 billion. Equities research analysts forecast that GE HealthCare Technologies Inc. will post 4.68 EPS for the current year.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.